Liu Qiang, Chairman of YaoPharma, said: "By leveraging Pfizer's exceptional global development experience and commercialisation network, along with YaoPharma's profound expertise in small molecule R&D and manufacturing, our shared goal is to accelerate the global development and commercialisation of this innovative drug, thereby benefiting patients worldwide more rapidly and extensively." Pfizers moves with Metsera and now YaoPharma add to continued competition in the obesity drug market, which has also seen Teva Pharmaceuticals gain US Food and Drug Administration (FDA) approval in August of a generic GLP-1 of its version of Novo Nordisks injectable Saxenda (liraglutide).
A single 10mg CagriSema vial at C$145.00 is the unit purchase
Paolisso G, et al
Final thoughts If youre reading this because youre considering GLP-1 therapy, or already using it and want a more comprehensive approach, here are key take-aways: GLP-1s can be powerful tools for glycemic control and weight/metabolic healthbut they carry side-effects and nutrient risks
7 Conclusion Systemic lupus erythematosus is a multicausal autoimmune disorder with pathogenesis strongly associated with intestinal flora dysbiosis, immune imbalance, and metabolic dysregulation
,aspect=fit)
